Moderately Potent (Medium-Strength) Topical Corticosteroids
Moderately potent topical corticosteroids include fluticasone propionate 0.05% cream, hydrocortisone butyrate 0.1%, prednicarbate 0.1%, triamcinolone acetonide 0.1%, and fluocinolone acetonide 0.025%. 1, 2
Classification and Examples
Topical corticosteroids are classified into 7 classes based on potency, with Class I being very high potency and Class VII being very low potency. Medium-potency corticosteroids fall into Classes IV-V and represent an optimal balance between efficacy and safety for longer-term use. 1, 2
Specific Medium-Potency Agents Include:
- Fluticasone propionate 0.05% (cream or ointment)
- Hydrocortisone butyrate 0.1% (cream, ointment, or solution)
- Prednicarbate 0.1% (cream or ointment)
- Triamcinolone acetonide 0.1% (cream or ointment)
- Fluocinolone acetonide 0.025% (cream or ointment)
- Hydrocortisone valerate 0.2% (cream or ointment)
- Flurandrenolide 0.05% (cream or ointment)
- Betamethasone valerate 0.12% (foam)
Clinical Advantages of Medium-Potency Corticosteroids
Medium-potency topical corticosteroids can be utilized for longer courses due to a more favorable adverse event profile compared to high or very high potency agents. 1 This makes them particularly suitable for:
- Maintenance therapy: High-certainty evidence strongly supports intermittent use (twice weekly) to reduce disease flares and relapse 1
- Facial and intertriginous areas: Where lower potency is preferred to minimize atrophy risk
- Pediatric populations: Where safety considerations are paramount
- Extended treatment courses: Beyond the 2-4 week limitation of ultra-high potency agents
Evidence-Based Efficacy
Research demonstrates that moderate-potency topical corticosteroids result in significantly more patients achieving treatment success (52% versus 34%) compared to mild-potency agents (OR 2.07,95% CI 1.41-3.04). 3 This represents a clinically meaningful improvement while maintaining an acceptable safety profile.
Key Clinical Consideration:
Fluticasone propionate 0.05% specifically has strong evidence for maintenance therapy, with patients 7.0 times less likely to experience relapse when used intermittently (once daily 2 days per week) compared to vehicle. 1
Safety Profile
The risk of abnormal skin thinning with medium-potency corticosteroids is substantially lower than with high or very high potency agents. In trials evaluating various potencies, only 2 cases of skin thinning were reported with moderate-potency agents out of 2,266 participants, compared to 16 cases with very potent and 6 cases with potent corticosteroids. 3